All In Biotech

NDA 207958 · Aprecia Pharms

Spritam

Levetiracetam · Oral

Last checked: Nov 20, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 31, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

261

71 Phase 3, 26 recruiting

FAERS reports

78,658

69,610 serious, 7,205 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2025.

SPRITAM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older weighing more than 20 kg ( 1.1 ) SPRITAM is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 ) 1.1 Partial-Onset Seizures SPRITAM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older weighing more than 20 kg. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy SPRITAM is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures SPRITAM is indicated as adjunctive therapy for the treatment of primary generalized tonic‑clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.

Mechanism: The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SPRITAM · LEVETIRACETAM 1GM · TABLET, FOR SUSPENSION, ORAL · Discontinued
  • SPRITAM · LEVETIRACETAM 500MG · TABLET, FOR SUSPENSION, ORAL · Prescription
  • SPRITAM · LEVETIRACETAM 750MG · TABLET, FOR SUSPENSION, ORAL · Discontinued
  • SPRITAM · LEVETIRACETAM 250MG · TABLET, FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levetiracetam" as an intervention, any sponsor and status, largest first.

All 261 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,217
  • seizure8,989
  • off label use6,640
  • maternal exposure during pregnancy3,194
  • epilepsy2,826
  • foetal exposure during pregnancy2,642
  • drug interaction2,532
  • fatigue2,503
  • condition aggravated2,343
  • somnolence2,132
  • status epilepticus2,102
  • generalised tonic-clonic seizure2,051

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200487
2005118
200693
2007161
2008212
2009665
2010685
2011994
20121,435
20131,616
20141,555
20152,386
20163,297
20174,571
20187,115
20197,971
20206,822
20216,810
20226,133
20236,864
20247,543
20256,511
20265,011

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Spritam (Levetiracetam)

2024 spending

$1.5M

Beneficiaries

347

1,498 claims

Per beneficiary

$4,262

$10.47 per unit

View as table
YearSpending
2020$287,928
2021$478,395
2022$963,727
2023$1,356,319
2024$1,478,997

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 772 on PubMed

Sponsor: Aprecia Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.